On January 9, 2023, it was announced that Stanford University and The Invus Group, an investment firm, have formed a collaboration to develop treatments for glioblastoma, a type of brain cancer. Invus is funding two projects at the Stanford Innovative Medicines Accelerator (IMA), both to develop a small-molecule or protein drug prototype that treats the disease. The prototypes are expected to be further developed through the formation of one or two new companies. Glioblastoma accounts for nearly half of all brain tumors, and little effective treatment is currently available. The National Brain Tumor Society estimates that more than 13,000 U.S. residents will be diagnosed with glioblastoma this year; the average survival after diagnosis is only eight months.
Login Or Register To Read Full Story